Johnson & Johnson Eyes $10B+ Acquisition of Intra-Cellular Therapies, Signaling a Potential Surge in 2025 Biotech M&A

　　Cailian Press, January 13 (Editor Zhaohao Zhao)According to media reports, informed sources revealed that Johnson & Johnson is planning to acquire the U.S. biopharmaceutical company Intra-Cellular Therapies for $10 billion, which is expected to become the largest biotechnology deal in more than a year.

Two知情人士表示，两家公司正在就潜在的交易进行谈判，可能最早于本周官宣。日内晚些时候，第43届摩根大通医疗健康大会将在美国加州揭幕，并购交易很可能会在会议上公布。

As of press time, Intra-Cellular Therapies (stock code: ITCI) rose nearly 36% in pre-market trading, with its stock price set to continue reaching new all-time highs. The stock closed up nearly 15% last Friday, and the company's market value has slightly exceeded 10 billion US dollars.

　　Intra-Cellular Therapies Daily Stock Price Chart

If the acquisition deal goes through, it will become the largest biotechnology transaction since Pfizer's $43 billion acquisition of Seagen in 2023. For Johnson & Johnson, the last deal of this scale was the $30 billion acquisition of Swiss company Actelion in 2017.

The insider added that Johnson & Johnson might offer a price higher than 10 billion US dollars. However, the negotiation could still break down, and there might be another buyer.

According to reports, Intra-Cellular Therapies (referred to as "ITCI" below) is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system (CNS) disorders.

ITCI's most significant drug is CAPLYTA (lumateperone), an oral, once-daily atypical antipsychotic that has received approval from the U.S. FDA for the treatment of schizophrenia and as an adjunctive therapy for schizophrenia and depressive episodes associated with bipolar I or II disorder in adults.

In 2023, CAPLYTA generated $464 million in sales for ITCI. In June of last year, ITCI also submitted an application to the FDA for the use of CAPLYTA as an adjunctive treatment for major depressive disorder, which is expected to expand the drug's market.

Last week, ITCI resolved its patent dispute with Sandoz, the leading generic drug company, which agreed not to launch a generic version of CAPLYTA before 2040. This news also paves the way for Johnson & Johnson's potential acquisition.

Media analysis suggests that if the deal is reached, it could revitalize merger and acquisition activities in the biotechnology sector. In 2024, large pharmaceutical groups spent only $45 billion across a total of 30 deals, down from $84 billion the previous year.

Due to the return of U.S. President-elect Donald Trump to the White House, there are expectations for a stock market boom,Interest RateThe downward forecast, along with its deregulatory policy agenda, will drive a recovery in M&A transactions by 2025.

Like other pharmaceutical manufacturers, Johnson & Johnson also faces the dilemma of the "patent cliff." Data from Wall Street investment bank Oppenheimer shows that when Johnson & Johnson loses the patent for DARZALEX, a drug for drug-resistant multiple myeloma, the company will lose $17 billion in revenue in 2029.

According to analysts' estimates, Johnson & Johnson has approximately $120 billion in financial firepower, which can enhance the value of the company's drug pipeline. Last year, the company spent $13.1 billion to acquire Shockwave Medical, a manufacturer of cardiac devices.